SEC Filing Summary: Rexahn Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on July 8, 2009, reporting events occurring on July 7, 2009. The filing addresses the status of the Company's common stock listing on the NYSE Amex (formerly the American Stock Exchange).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock exchange listing requirements.
Material Changes
- Delisting Notice: On February 24, 2009, the Company received notice from the NYSE Amex that it was not in compliance with the Company Guide, placing its common stock at risk of delisting.
- Regained Compliance: On July 7, 2009, the Exchange notified the Company that it had regained compliance with the listing requirements.
- Current Status: The Company's common stock is no longer subject to delisting.
Outlook and Risks
The filing confirms the resolution of the immediate risk of delisting. No forward-looking guidance, management commentary on financial performance, or discussion of other contingencies is included in this specific report. A press release regarding this event is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the specific compliance metrics (e.g., stock price, shareholder equity, or market capitalization) that the Company met to regain listing status.
- Review the attached press release (Exhibit 99.1) for details on the Company's plan to maintain compliance.
- Confirm the current trading status of the stock on the NYSE Amex following the July 7 notification.